Why biomanufacturing is important for Canada
Canada played an essential role in the development and global production of biopharmaceuticals for the better part of the 20th century. During the 1980s, it began to shift focus to other areas of research and development in the life sciences sector. In 1973, less than 20% of Canada's domestic demand for vaccines and therapeutic drugs was supplied through imports. Today, Canada imports 85% of its requirements.
The Government of Canada recognizes that a robust domestic biomanufacturing sector is critical to ensuring future pandemic preparedness. As a result, it is investing in made-in-Canada projects to protect Canadians from COVID-19 and ensure our country is well positioned to fight future pandemics here at home.
Investments in biomanufacturing will:
- Enhance capacity to manufacture domestic and international vaccine and therapeutic candidates as soon as they are available.
- Minimize supply chain risks and border disruptions.
- Secure Canada's role as an integral part of the international biologics supply chain by bringing Canadian products from research to market.
- Ensure adherence to high-quality manufacturing standards, which are key to Health Canada's approval process.
- Create good, well-paying jobs and provide long-term economic benefits to Canadians.
- Create a long-term approach for Canada's pandemic preparedness.
- Date modified: